---
title: "Jiangxi Bio rises 8% on vet antitoxin approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292716396.md"
description: "Jiangxi Bio climbed 8.64% to HK$4.890 in Hong Kong trading after a subsidiary received approval for veterinary tetanus antitoxin."
datetime: "2026-07-15T05:40:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292716396.md)
  - [en](https://longbridge.com/en/news/292716396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292716396.md)
generator: "portal-rs"
---

# Jiangxi Bio rises 8% on vet antitoxin approval

Jiangxi Bio (6915.HK) **climbed** **8%** during regular trading to **HK$4.890**.

The surge followed news that a subsidiary recently received approval for veterinary tetanus antitoxin, serving as the primary catalyst for the stock's movement.

### Related Stocks

- [06915.HK](https://longbridge.com/en/quote/06915.HK.md)

## Related News & Research

- [Jiangxi Institute of Biological Products schedules board meeting to release interim results](https://longbridge.com/en/news/296077099.md)
- [Impact Therapeutics added to Shanghai, Shenzhen Stock Connect eligible list from Sept. 7, 2026](https://longbridge.com/en/news/298163872.md)
- [08:17 ETHBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study](https://longbridge.com/en/news/298317987.md)
- [Hansoh Pharma says China NMPA accepts BLA for HS-20093 in small cell lung cancer](https://longbridge.com/en/news/298175855.md)
- [Qurient Plans Investor Roadshow at 2026 KIS BioTech Day in Singapore and Hong Kong](https://longbridge.com/en/news/298160024.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**